Macrocyclic inhibitors of the PD-1/PD-l1 and CD80(B7-1)/PD-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Saved in:
Bibliographic Details
Main Authors J. ZHU, MULL ERIC, BOY KENNETH M, SCOLA PAUL MICHAEL, YEUNG KAP-SUN, BOWSHER MICHAEL S, SANGHVI NISHITH, REID PATRICK C, SUN LI-QIANG, MILLER MICHAEL MATTHEW, TENNEY DANIEL J, POIRIER MAUDE A, GILLIS ERIC P, LANGLEY DAVID R, MAPELLI CLAUDIO, ALLEN MARTIN PATRICK
Format Patent
LanguageEnglish
Published 30.12.2015
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Bibliography:Application Number: CN201480027014